AstraZeneca’s Tagrisso Plus Chemotherapy Receives Japanese Approval to Treat EGFR-Mutated Advanced Lung Cancer
Shots:
- Approval was based on P-III (FLAURA2) study of Tagrisso (80mg, oral, QD) + CT (pemetrexed: 500mg/m^2 + cisplatin: 75mg/m^2 or carboplatin), Q3W followed by Tagrisso with pemetrexed maintenance as a 1L treatment of patients (n=557) with locally advanced (stage IIIB-IIIC) or metastatic (stage IV) EGFRm NSCLC
- Study depicted a 38% reduced disease progression or death risk with mPFS of 25.5mos. (Tagrisso + CT) vs 16.7mos. (Tagrisso alone) during investigator evaluation; similar PFS with mPFS of 29.4mos. vs 19.9mos. was seen during an independent central review
- A favorable trend was observed in OS benefit with 41% maturity during 2nd interim analysis; further OS evaluation is underway
Ref: Astrazeneca | Image: Astrazeneca
Related News:- AstraZeneca Reports Updated Data from the P-III (ADJUVANT BR.31) Study of Imfinzi to Treat Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
